Sequella, Inc.
9610 Medical Center Drive, Suite 200
Rockville
Maryland
20850
United States
Tel: 301-762-7776
Fax: 301-762-7778
Website: http://www.sequella.com/
Email: mail@sequella.com
21 articles about Sequella, Inc.
-
Vaccine-Fixated Pfizer Inc. Licenses Out TB Drug to Sequella, Inc.
7/17/2013
-
Biotech Venture Fund's Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed From Sequella, Inc.
12/19/2012
-
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella, Inc.'s Antibiotic, SQ109, for Tuberculosis
7/26/2012
-
Sequella, Inc. Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary; Deal Valued at Over $100 Million to the Parties
4/25/2011
-
Sequella, Inc. Awarded $4.6 Million in New National Institutes of Health (NIH) Grants to Expand Anti-Infectives Pipeline
4/4/2011
-
John H. Friedman of Easton Capital Investment Group Joins Sequella, Inc. Board of Directors
1/31/2011
-
Sequella, Inc. Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers
12/6/2010
-
Sequella, Inc. Receives International Support for Phase 2 Clinical Trials of SQ109, its Lead Antitubercular Drug Candidate
10/18/2010
-
Sequella, Inc.: Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
7/26/2010
-
Sequella, Inc. and National Institutes of Health (NIH) Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
11/17/2009
-
Sequella, Inc. Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
10/12/2009
-
Sequella, Inc. Receives American Recovery and Reinvestment Funding Through the National Institutes of Health (NIH) Grant Funds to Finalize Synthetic Manufacturing Process for Promising New TB Drug Candidate
10/5/2009
-
Sequella, Inc. Receives American Recovery and Reinvestment Funding Through the National Institutes of Health (NIH) Grant Funds to Finalize Synthetic Manufacturing Process for Promising New TB Drug Candidate
10/5/2009
-
Sequella, Inc. Commences Phase 1B Study for New Tuberculosis Drug SQ109
5/5/2009
-
Infectious Diseases Company, Sequella, Inc., to Present at Upcoming European Conferences
3/3/2009
-
Sequella, Inc. Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
1/6/2009
-
Sequella, Inc. Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
11/17/2008
-
Sequella, Inc. Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
10/29/2008
-
Sequella, Inc. Lead Drug Compound SQ109 Receives Orphan Drug Status From the FDA and Orphan Medicinal Product Designation From the European Medicines Evaluation Agency for the Treatment of Tuberculosis
10/22/2007
-
Sequella, Inc. Lead TB Drug SQ109 Completes Phase 1a Trial
5/3/2007